Health
Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies – News-Medical.Net
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-ca…
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.
According to WHO reports, the current COVID-19 (coronavirus disease 2019) pandemic has caused more…
-
Business21 hours agoThe ultimate Australian stocks to buy and hold for 10+ years
-
Noosa News17 hours agoSouthern NSW farmers call for financial relief as ongoing drought takes a toll
-
Noosa News17 hours agoLNP Premier David Crisafulli announces ‘Queensland’s royal commission’ into CFMEU
-
General23 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project